Vor Biopharma (VOR) Income towards Parent Company (2020 - 2026)

Vor Biopharma (VOR) has reported Income towards Parent Company for 7 consecutive years, with -$31.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 8.31% year-over-year to -$31.3 million; the TTM figure through Mar 2026 stood at -$375.0 million (down 203.16% YoY), while the FY2025 annual figure was -$598.5 million, down 133.68% from the prior year.
• Income towards Parent Company rose to -$31.3 million in Q1 2026 per VOR's latest filing, from -$33.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$23.0 million in Q2 2022 and bottomed at -$283.9 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$44.2 million across 5 years, with a median of -$30.0 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 89.35% — and 2025, when it sank 917.39%.
• Vor Biopharma's Income towards Parent Company stood at -$26.6 million in 2022, then decreased by 7.62% to -$28.7 million in 2023, then slipped by 13.05% to -$32.4 million in 2024, then decreased by 2.71% to -$33.3 million in 2025, then increased by 5.83% to -$31.3 million in 2026.
• Business Quant data shows VOR's Income towards Parent Company at -$31.3 million in Q1 2026, -$33.3 million in Q4 2025, and -$26.4 million in Q3 2025.